A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia

NCT04899310 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
18
Enrollment
INDUSTRY
Sponsor class

Stopped As part of ongoing efforts to refine the MMA program strategy, we are reevaluating clinical study plans for mRNA-3705, in order to further optimize the development program. As part of this process, Moderna will be closing the mRNA-3705-P101 study.

Conditions

Interventions

Sponsor

ModernaTX, Inc.